IMPROVING
CANCER TREATMENT
Sox Therapeutics was founded in 2025 and is developing targeted gene therapies for malignant brain tumors. The therapies are innovative and based on tailored adeno-associated viral (AAV) approaches. The treatments are developed based on important findings from two decades of intense research at Uppsala University on how therapy resistance develops in patients with brain cancer.
BOARD & MANAGEMENT team
FREDRIK Swartling
Chief Executive Officer, Founder
Board Member
Assoc. Professor,
Uppsala University, Sweden
Mateo Santurio
Board Member
Business Advisor
christina herder
Board Member
Business Advisor
SCIENTIFIC TEAM
Tina LIN
Scientific Researcher
Viral Vector Design
tobias bergström
Clinical Study Lead
Clinical Study Coordinator
sonja hutter
Co-Inventor, Scientific Advisor
Molecular Genetics and Diagnostics
ADVISORs
Annika ericsson
AAV Gene Therapy Expert
CMC Drug Development
Mats hellström
Medical Advisor
Adult Brain Tumor Treatment
and Immunotherapies
Get in Touch Today!
Questions to us? Fill out the form below and our team will get back to you promptly.
